JP2015516980A5 - - Google Patents

Download PDF

Info

Publication number
JP2015516980A5
JP2015516980A5 JP2015507531A JP2015507531A JP2015516980A5 JP 2015516980 A5 JP2015516980 A5 JP 2015516980A5 JP 2015507531 A JP2015507531 A JP 2015507531A JP 2015507531 A JP2015507531 A JP 2015507531A JP 2015516980 A5 JP2015516980 A5 JP 2015516980A5
Authority
JP
Japan
Prior art keywords
antibody
bendamustine
pharmaceutical composition
seq
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015507531A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015516980A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/058617 external-priority patent/WO2013160396A1/en
Publication of JP2015516980A publication Critical patent/JP2015516980A/ja
Publication of JP2015516980A5 publication Critical patent/JP2015516980A5/ja
Pending legal-status Critical Current

Links

JP2015507531A 2012-04-26 2013-04-25 Cd37抗体とベンダムスチンとの併用 Pending JP2015516980A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12165660.7 2012-04-26
EP12165660 2012-04-26
EP12168397.3 2012-05-16
EP12168397 2012-05-16
PCT/EP2013/058617 WO2013160396A1 (en) 2012-04-26 2013-04-25 Combination of cd37 antibodies with bendamustine

Publications (2)

Publication Number Publication Date
JP2015516980A JP2015516980A (ja) 2015-06-18
JP2015516980A5 true JP2015516980A5 (enExample) 2016-07-07

Family

ID=48227255

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015507531A Pending JP2015516980A (ja) 2012-04-26 2013-04-25 Cd37抗体とベンダムスチンとの併用

Country Status (4)

Country Link
US (2) US20130287797A1 (enExample)
EP (1) EP2841099A1 (enExample)
JP (1) JP2015516980A (enExample)
WO (1) WO2013160396A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20140196A1 (es) 2007-08-09 2014-03-19 Boehringer Ingelheim Int Anticuerpos anti-cd37
WO2013171287A1 (en) 2012-05-16 2013-11-21 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide)
JP2015517512A (ja) * 2012-05-16 2015-06-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cd37抗体の更なる薬剤との併用
US11021537B2 (en) * 2017-05-01 2021-06-01 Agenus Inc. Anti-TIGIT antibodies and methods of use thereof
TW202304965A (zh) 2021-05-04 2023-02-01 美商艾吉納斯公司 抗tigit抗體、抗cd96抗體及其使用方法
KR20250175330A (ko) * 2023-04-19 2025-12-16 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트와 다른 약제의 조합

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
DK0563475T3 (da) 1992-03-25 2000-09-18 Immunogen Inc Konjugater af cellebindende midler og derivater af CC-1065
DE19911329A1 (de) 1998-03-27 2000-09-21 Benes Ivan Friedrich Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
NZ517772A (en) 1999-11-24 2004-03-26 Immunogen Inc Cytotoxic agents comprising taxanes and their therapeutic use
EP1242438B1 (en) 1999-12-29 2006-11-08 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
US6596757B1 (en) 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
JP4703566B2 (ja) 2003-05-14 2011-06-15 イムノゲン インコーポレーティッド 薬剤複合体組成物
ES2460517T3 (es) * 2005-07-25 2014-05-13 Emergent Product Development Seattle, Llc Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
PE20140196A1 (es) * 2007-08-09 2014-03-19 Boehringer Ingelheim Int Anticuerpos anti-cd37
PT2132228E (pt) * 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
US20120189618A1 (en) * 2010-07-16 2012-07-26 Boehringer Ingelheim International Gmbh Superior efficacy of cd37 antibodies in cll blood samples
JP2015517512A (ja) * 2012-05-16 2015-06-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cd37抗体の更なる薬剤との併用

Similar Documents

Publication Publication Date Title
JP2015517511A5 (enExample)
JP2015516980A5 (enExample)
RU2019138710A (ru) Антитела, специфичные к flt3, и их применения
JP2015517512A5 (enExample)
JP2018184417A5 (enExample)
JP2017507954A5 (enExample)
JP2014114288A5 (enExample)
RU2015112576A (ru) Комбинированная терапия с использованием антитела против cd20 типа ii и селективного ингибитора bcl-2
Tanasescu et al. Advances in the treatment of relapsing-remitting multiple sclerosis
JP2019517485A5 (enExample)
JP2015523380A5 (enExample)
JP2015527318A5 (enExample)
JP2019517549A5 (enExample)
CN111065411A (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
JP2016536314A5 (enExample)
JP2009519257A5 (enExample)
CN103732252B (zh) 使用抗cd‑19抗体和氮芥的联合治疗
JP2010529026A5 (enExample)
AU2024287178A1 (en) Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
JP2020524670A5 (enExample)
RU2014117510A (ru) Лечение ревматоидного артрита
JP2019533682A5 (enExample)
JP2014525926A5 (enExample)
JP2015172060A5 (enExample)
JP2020523384A5 (enExample)